FDA Accepts BioCryst ’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news